Stalled at the FDA, Amicus adds a preclinical rare disease drug in back-ended $90M deal
Amicus Therapeutics $FOLD has snagged a preclinical drug in a small biotech buyout, beefing up its slim pipeline at a time that the company is still assessing just how badly its lead drug may have stalled in front of the FDA.
The Cranbury, NJ-based biotech acquired MiaMed for $1.8 million in cash, $4.7 million in Amicus stock and up to $83 million in development and commercialization milestones. The bulk of the money is back-ended to the commercialization stage.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.